A MODULAR PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, AND PRELIMINARY EFFICACY OF AZD4512 MONOTHERAPY OR IN COMBINATION WITH ANTICANCER AGENT(S) IN PARTICIPANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Registry ID

D9891C00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2026-01-07

Last update

2025-09-12

Conditions

• ACUTE LYMPHOBLASTIC LEUKEMIA

Related clinical trials

• A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
• RE-TREATMENT WITH SECOND GENERATION, ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS IN RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ACIT001-3)
• A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AZD0486 IN ADOLESCENT AND ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
• A RANDOMIZED TRIAL OF LEVOCARNITINE PROPHYLAXIS TO PREVENT ASPARAGINASE-ASSOCIATED HEPATOTOXICITY IN ADOLESCENTS AND YOUNG ADULTS RECEIVING ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY
• A PHASE IB STUDY OF THE PHARMACOKINETICS, SAFETY AND EFFICACY OF ORALLY ADMINISTERED HQP1351 IN SUBJECTS WITH REFRACTORY CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
• A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ADMINISTRATION OF SUBCUTANEOUS BLINATUMOMAB FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B ALL

View on source registry